Understanding Financial Aspects of IBD Through Bio-Medicines and Biosimilars

Upcoming Lecture Series: IBD and Financial Support

Introduction

Managing inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, has become increasingly complex as more treatment options become available. To support patients and families facing the financial aspects of these treatments, Celltrion Healthcare Japan and Goodte Co., Ltd. have teamed up to offer a three-part lecture series titled IBD and Money. The second lecture, focused on bio-medicines and biosimilars, will be conducted by Dr. Ken Takeuchi from Tsujinaka Hospital Kashiwanoha.

Event Details

Scheduled for March 15, 2026, this lecture will run from 14:00 to 15:10 and will be hosted as an online Zoom webinar. Participation is free but requires prior registration. To participate, please sign up via the provided link: Webinar Registration.

Background on IBD

As IBD prevalence continues to rise, new research and treatment options offer hope. However, many available treatments can be financially burdensome due to their high costs. IBD is classified as a rare disease in Japan, leading to government funding for medical expenses, but this financial support is increasingly strained as the fiscal burden on the government grows each year. Moreover, patients deemed to have mild cases of IBD often do not qualify for these subsidies, further increasing out-of-pocket costs.

Lecture Focus

In this second session, Dr. Takeuchi will illuminate the role of bio-medicines and biosimilars in IBD treatment. Attendees will gain insights into how these advanced therapies are approved and incorporated into patient treatment plans. This session aims to empower patients and their families with knowledge about financial management concerning these treatments.

Discussion Session

The latter part of the lecture will consist of a Q&A session where Dr. Takeuchi will address concerns related to treatment approval processes and other anxieties that patients may have concerning their care plans. This interactive segment is particularly valuable, as it provides a platform for attendees to raise specific questions and engage directly with a seasoned expert in the field.

Purpose and Goals

The IBD and Money series seeks to delve into the challenges surrounding the financial implications of IBD treatment and living. By educating participants about the economics of care, the series aspires to find ways to enhance sustainability in treatment and living strategies for patients navigating this difficult landscape.

Conclusion

This is an excellent opportunity for those affected by IBD to reflect on the financial intricacies of treatment. We encourage all patients, their families, and caregivers to join us and gain invaluable knowledge that can aid in coping with the complexities of IBD.

About the Organizers

Celltrion Healthcare Japan Co., Ltd. is a leading biopharmaceutical company known for its work in developing various bio-medicines and biosimilars aimed at chronic conditions like IBD, rheumatoid arthritis, and cancer. Their mission revolves around enhancing patient health and well-being through innovative therapies.

Goodte Co., Ltd. was founded by Takuro Miyazaki and Noriyuki Suzuki in September 2018. The company has built a community for IBD patients and families, fostering cooperation between medical professionals and patients. They have launched resources such as the G Community and created patient-driven recipes to improve daily management of IBD. Visit their website for more details: Goodte.

For any inquiries regarding the lecture event, please contact the Goodte representatives, Miyazaki and Morimoto, at [email protected].